Celldex Therapeutics Inc. (CLDX)
Celldex Therapeutics Statistics
Share Statistics
Celldex Therapeutics has 66.34M shares outstanding. The number of shares has increased by 2.99% in one year.
| Shares Outstanding | 66.34M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.09% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 64.70M |
| Failed to Deliver (FTD) Shares | 5.29K |
| FTD / Avg. Volume | 0.5% |
Short Selling Information
The latest short interest is 7.31M, so 11.02% of the outstanding shares have been sold short.
| Short Interest | 7.31M |
| Short % of Shares Out | 11.02% |
| Short % of Float | 11.3% |
| Short Ratio (days to cover) | 7.07 |
Valuation Ratios
The PE ratio is -13.59 and the forward PE ratio is -8.36.
| PE Ratio | -13.59 |
| Forward PE | -8.36 |
| PS Ratio | 279.16 |
| Forward PS | 574.6 |
| PB Ratio | 4.48 |
| P/FCF Ratio | -17.61 |
| PEG Ratio | n/a |
Enterprise Valuation
Celldex Therapeutics Inc. has an Enterprise Value (EV) of 1.89B.
| EV / Earnings | -13.36 |
| EV / Sales | 274.48 |
| EV / EBITDA | -13.59 |
| EV / EBIT | -12.22 |
| EV / FCF | -17.31 |
Financial Position
The company has a current ratio of 13.87, with a Debt / Equity ratio of 0.01.
| Current Ratio | 13.87 |
| Quick Ratio | 13.87 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.59 |
| Cash Flow / Debt | -42.21 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.33% and return on capital (ROIC) is -35.8%.
| Return on Equity (ROE) | -0.33% |
| Return on Assets (ROA) | -0.3% |
| Return on Capital (ROIC) | -35.8% |
| Revenue Per Employee | 43.02K |
| Profits Per Employee | -883.93K |
| Employee Count | 160 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -32.46% in the last 52 weeks. The beta is 1.59, so Celldex Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.59 |
| 52-Week Price Change | -32.46% |
| 50-Day Moving Average | 25.62 |
| 200-Day Moving Average | 33.34 |
| Relative Strength Index (RSI) | 47.46 |
| Average Volume (20 Days) | 1.07M |
Income Statement
In the last 12 months, Celldex Therapeutics had revenue of 6.88M and earned -141.43M in profits. Earnings per share was -2.92.
| Revenue | 6.88M |
| Gross Profit | 3.88M |
| Operating Income | -154.54M |
| Net Income | -141.43M |
| EBITDA | -139.03M |
| EBIT | -154.54M |
| Earnings Per Share (EPS) | -2.92 |
Balance Sheet
The company has 34.81M in cash and 2.54M in debt, giving a net cash position of 32.27M.
| Cash & Cash Equivalents | 34.81M |
| Total Debt | 2.54M |
| Net Cash | 32.27M |
| Retained Earnings | -1.40B |
| Total Assets | 823.18M |
| Working Capital | 746.75M |
Cash Flow
In the last 12 months, operating cash flow was -107.29M and capital expenditures -1.82M, giving a free cash flow of -109.11M.
| Operating Cash Flow | -107.29M |
| Capital Expenditures | -1.82M |
| Free Cash Flow | -109.11M |
| FCF Per Share | -2.25 |
Margins
Gross margin is 56.3%, with operating and profit margins of -2.25K% and -2.05K%.
| Gross Margin | 56.3% |
| Operating Margin | -2.25K% |
| Pretax Margin | -2.05K% |
| Profit Margin | -2.05K% |
| EBITDA Margin | -2.02K% |
| EBIT Margin | -2.25K% |
| FCF Margin | -1.59K% |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -11.88% |
| FCF Yield | -6.69% |
Analyst Forecast
The average price target for CLDX is $68.5, which is 178.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $68.5 |
| Price Target Difference | 178.8% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Feb 11, 2019. It was a backward split with a ratio of 1:15.
| Last Split Date | Feb 11, 2019 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | 23.49 |
| Piotroski F-Score | 3 |